November 30, 2023

Letter seeks clarity on semaglutide compounding in California

Last week, we sent a letter to the California Board of Pharmacy requesting clarification of its position on compounding semaglutide.

The letter is the result of several reports of conflicting statements from California BOP staff that seemed to deviate from current FDA guidance on shortage drug compounding.